Anti-SUCO monoclonal antibody

Pre-made anti-SUCO monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to SUCO/SUCO products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1853-Ab-1/ GM-Tg-hg-IP1853-Ab-2Anti-Human SUCO monoclonal antibodyHuman
GM-Tg-rg-IP1853-Ab-1/ GM-Tg-rg-IP1853-Ab-2Anti-Rat SUCO monoclonal antibodyRat
GM-Tg-mg-IP1853-Ab-1/ GM-Tg-mg-IP1853-Ab-2Anti-Mouse SUCO monoclonal antibodyMouse
GM-Tg-cynog-IP1853-Ab-1/ GM-Tg-cynog-IP1853-Ab-2Anti-Cynomolgus/ Rhesus macaque SUCO monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1853-Ab-1/ GM-Tg-felg-IP1853-Ab-2Anti-Feline SUCO monoclonal antibodyFeline
GM-Tg-cang-IP1853-Ab-1/ GM-Tg-cang-IP1853-Ab-2Anti-Canine SUCO monoclonal antibodyCanine
GM-Tg-bovg-IP1853-Ab-1/ GM-Tg-bovg-IP1853-Ab-2Anti-Bovine SUCO monoclonal antibodyBovine
GM-Tg-equg-IP1853-Ab-1/ GM-Tg-equg-IP1853-Ab-2Anti-Equine SUCO monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1853-Ab-1/ GM-Tg-hg-IP1853-Ab-2; GM-Tg-rg-IP1853-Ab-1/ GM-Tg-rg-IP1853-Ab-2;
GM-Tg-mg-IP1853-Ab-1/ GM-Tg-mg-IP1853-Ab-2; GM-Tg-cynog-IP1853-Ab-1/ GM-Tg-cynog-IP1853-Ab-2;
GM-Tg-felg-IP1853-Ab-1/ GM-Tg-felg-IP1853-Ab-2; GM-Tg-cang-IP1853-Ab-1/ GM-Tg-cang-IP1853-Ab-2;
GM-Tg-bovg-IP1853-Ab-1/ GM-Tg-bovg-IP1853-Ab-2; GM-Tg-equg-IP1853-Ab-1/ GM-Tg-equg-IP1853-Ab-2
Products NameAnti-SUCO monoclonal antibody
Formatmab
Target NameSUCO
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-SUCO monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1853-Ag-1Recombinant multi-species SUCO/ C1orf9/ CH1 protein


    Target information

    Target IDGM-IP1853
    Target NameSUCO
    Gene ID51430,226551,360863,705776,480071,101091496,520588,100060398
    Gene Symbol and Synonyms4732491B11,C1H1orf9,C1orf9,C7H1orf9,CH1,Dd25,OPT,SLP1,SUCO
    Uniprot AccessionQ9UBS9,Q710E6
    Uniprot Entry NameSUCO_HUMAN,SUCO_RAT
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000094975
    Target ClassificationN/A

    The target: SUCO, gene name: SUCO, also named as C1orf9, CH1, OPT, SLP1. Predicted to be involved in positive regulation of collagen biosynthetic process; positive regulation of osteoblast differentiation; and regulation of bone remodeling. Predicted to be located in rough endoplasmic reticulum. Predicted to be active in cytoplasm and membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.